title: Editorial commentary: protease inhibitor monotherapy: safe for the CNS in durably suppressed patients?
authors.affiliation: University of California, San Diego, California.
authors.forename: Scott L
authors.initials: SL
authors.lastname: Letendre
mesh_terms: D003072:Cognition Disorders / Q000821:virology*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D006801:Humans; D008297:Male
chemical_list: D017320:HIV Protease Inhibitors
keywords: CNS; HIV; antiretroviral; dementia
references.citation: Antivir Ther. 2013;18(2):153-60
references.pmid: 23486721
references.citation: AIDS. 2014 Feb 20;28(4):493-501
references.pmid: 24472743
references.citation: Clin Infect Dis. 2014 Apr;58(7):1015-22
references.pmid: 24352352
references.citation: AIDS. 2007 Jun 19;21(10):1309-15
references.pmid: 17545707
references.citation: Arch Neurol. 2008 Jan;65(1):65-70
references.pmid: 18195140
references.citation: S Afr Med J. 2013 Sep 18;103(10):758-62
references.pmid: 24079630
references.citation: Neurology. 2007 Oct 30;69(18):1789-99
references.pmid: 17914061
references.citation: BMC Neurol. 2011 Nov 22;11:148
references.pmid: 22107790
references.citation: Scand J Infect Dis. 2012 Dec;44(12):997-1000
references.pmid: 22776013
references.citation: AIDS. 2010 Sep 24;24(15):2347-54
references.pmid: 20802298